Rankings
▼
Calendar
MDGL Q4 2025 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$321M
+210.8% YoY
Gross Profit
$297M
92.4% margin
Operating Income
-$60M
-18.6% margin
Net Income
-$59M
-18.2% margin
EPS (Diluted)
$-2.57
QoQ Revenue Growth
+11.8%
Cash Flow
Operating Cash Flow
-$133M
Free Cash Flow
-$133M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$657M
Stockholders' Equity
$603M
Cash & Equivalents
$199M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$321M
$103M
+210.8%
Gross Profit
$297M
$100M
+197.0%
Operating Income
-$60M
-$67M
+11.0%
Net Income
-$59M
-$59M
+1.4%
Revenue Segments
Reportable Segment
$458M
100%
← FY 2025
All Quarters